目的 探讨了血清CYFRA21-1、CA72-4、CA125同食管癌患者病理分期的相关性。方法 采用放射免疫分析法检测79例正常健康对照者、190例食管癌患者血清CA125、CA72-4和CYFRA21-1的浓度水平，同时采集患者病理分期资料并进行分析。结果 从数值来看CYFRA21-1、CA125、CA72-4随分期的增加其水平呈增高趋势。CYFRA21-1组中Ⅱa期（P﹤0.01）、Ⅲ（P﹤0.05）期、Ⅳ期（P﹤0.01）及淋巴结阳性组（P﹤0.01）同正常对照组比较有统计学意义；ⅡB、Ⅲ期、Ⅳ期同0期比较有统计学意义（P﹤0.01）；Ⅳ期同Ⅰ期比较有统计学意义（P﹤0.05）；CA125 Ⅳ期同0期比较有统计学意义（P﹤0.01）；CA72-4各组间均无统计学意义，三指标水平淋巴结阳性组同正常对照组比较有统计学意义（P﹤0.01）。CA125与不同pT分期具有明显相关性（r=0.210，P<0.05），余指标与分期均无相关性。结论 CYFRA21-1可以区分食管癌早期（0期和/或Ⅰ期）与晚期（ⅡB期，Ⅲ期，Ⅳ期），CA125可以区分食管癌0期与Ⅳ期；CA125与pT分期明显相关性。

Objectives To investigate the clinical value of the serum levels of CA125, CA72-4 and CYFRA21-1 in staging of esophageal cancer patients. Methods The serum levels of CA125, CA72-4 and CYFRA21-1 in 190 esophageal cancer patients and 79 healthy controls were measured by radioimmunoassay. The clinical pathological parameters in esophageal cancer patients were collected and analyzed. Results The serum levels of CYFRA21-1, CA72-4 and CA125 in esophageal cancer patients were increasing as their staging increased. The CYFRA21-1 levels in patients in stage of Ⅱa, Ⅲ, Ⅳ, and the lymph node positive group had statistical difference with the healthy control group (P<0.05). The CA125 levels in patients between stages of Ⅳ and Ⅰhad statistical difference（P﹤0.05）. The CA72-4 levels in patients in all stages had no statistical significant. Conclusion The serum CYFRA21-1 could be used to identify the early stage（stage 0 andⅠ）and advanced stage（stage ⅡB, Ⅲ and Ⅳ）. The serum CA125 might be used to identify the early stage and advanced stage, and the serum CA125 is obviously correlated with pT staging in esophageal cancer patients.